THRB and metabolic dysfunction-associated steatohepatitis: At week 12, mean changes from baseline in rT3 were decreased in all TERN-501 monotherapy and combination therapy groups, leading to increases in the fT3/rT3 ratio, suggesting that TERN-501 treatment may improve THRβ signaling and restore thyroid hormone levels within the liver in patients with MASH.